8-K - Drugs Made In America Acquisition Corp. Ordinary Shares | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Drugs Made In America Acquisition Corp. removed Lynn Stockwell as Chief Executive Officer, Executive Chair of the Board, and Board member on February 28, 2026, due to sponsor withdrawals and overpayments from an affiliate's working capital account. Roger Bendelac was appointed as the new Chief Executive Officer effective the same date.

Key Takeaways

1Lynn Stockwell resigned and was removed as CEO, Executive Chair, and Board member of the Company on February 28, 2026.

2Roger Bendelac, 69, appointed CEO of the Company effective February 28, 2026.

3Sponsor withdrew $1,100,000 from Affiliate’s working capital account between September 26 and September 30, 2025, including $325,000 to repay a note and $208,000 for offering costs.

4Sponsor received $566,269 overpayment and withdrew at least $200,000 more for unrelated expenses between September 30 and December 31, 2025.

5Affiliate Board directed Sponsor to return overpayment on February 12, 2026, but Sponsor could not repay.

6Mr. Bendelac has over 30 years in investment banking and serves as consultant/director at multiple firms since 2015.

Current Report Details

Event Type

Management Change

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

. Departures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previou

Management Change

Executive & Director Changes

Lynn Stockwell

Chief Executive Officer, Executive Chair of the Board, Board member

Removed (resignation tendered and accepted)

Effective: 2026-02-28

Sponsor withdrawals and overpayments from Affiliate’s working capital account

Roger Bendelac

Chief Executive Officer

Appointed

Effective: 2026-02-28

At request of Board following Ms. Stockwell’s removal

Exhibits (1)

8-K

CURRENT REPORT